Que suerte haber podido contar contigo, Erika, en mis primeros años organizando el nuevo lab en Barcelona. Siempre digo que no sé cómo lo hubiera hecho sin ti. Gracias por tu apoyo y buen humor. Ha sido un verdadero placer trabajar contigo. Te deseo toda la suerte del mundo!

El larguísimo trecho desde la ‘cura’ del cáncer en ratones hasta las personas La científica Laura Soucek, que eliminó tumores en roedores hace casi 20 años, invoca el “deber moral” de no generar falsas expectativas tras el anuncio de Mariano Barbacid

Gracias a @manuelansede.bsky.social y a @elpais.com. Solo quise recordar algo esencial: cuando están en juego esperanza y miedos de pacientes con cáncer, la información debe ser rigurosa, responsable y prudente.
elpais.com/ciencia/2026...

Very proud to be one of the Catalan awardees of the @erc.europa.eu Proof of Concept grants.
The grant #SonoMYC is built on the collaboration among @vhio.bsky.social, #Peptomyc and #Carthera.
Grateful to the #ERC for supporting us and honoured to be in the company of extraordinary colleagues.

Frontiers | MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance Immunotherapies have transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells, offering durable clinical benef...

New review just out in Frontiers in Immunology! 🎉

We dive into how #MYC reshapes the tumor–immune interface to drive #immuneescape and resistance to #immunotherapy.
Open access here 👉 www.frontiersin.org/journals/imm...
@vhio.bsky.social @icreacommunity.bsky.social @lsouceklab.bsky.social #peptomyc

SF was home for 10 years, and UCSF is where I trained and grew as a scientist. Grateful to bridge academia and biotech, past and present. #MYC #OMO103 #Biotech #TranslationalResearch

In parallel, I returned to @ucsfcancer.bsky.social, invited by @shulab2010.bsky.social, to give a talk on developing the first viable clinical #MYCinhibitor, #OMO-103, representing @vhio.bsky.social, @lsouceklab.bsky.social
and @icreacommunity.bsky.social.

Last week in San Francisco was intense, productive, and personally meaningful.

As CSO of #Peptomyc, , I joined our CEO @jesusmartingarcia.bsky.social during #JPMHealthcare week to meet with pharmaceutical companies and discuss potential strategic collaborations.
📍 San Francisco

2026-002-01 Research Laboratory Technician / Lab Manager - VHIO Under the leadership of Josep Tabernero, VHIO is an internationally recognized cancer center. Its multidisciplinary, collaborative model drives scientific progress and innovative cancer treatments.

We are hiring! If you are interested in joining our Models of Cancer Therapy Laboratory lab at @vhio.bsky.social as a Research Laboratory Technician / Lab Manager, apply here: jobs.vhio.net/en/jobs/7018...

Frontiers | The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated...

Really happy to share our new open-access review in Frontiers in Cell and Developmental Biology 🎉
#MYC inhibition creates vulnerabilities that can be targeted with #DDR inhibitors.
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc @lsouceklab.bsky.social
www.frontiersin.org/journals/cel...

Honored to deliver a keynote today at the 19th Scientific Day & 29th Annual Conference of Vall d’Hebron on collaborative, challenge-driven research with transformative health impact. #MYC #OMO-103 #Omomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc

Ayer, 3 de diciembre, participé como ponente en la XV edición del @cniostopcancer.bsky.social Lab Day, contando mi experiencia científica y emprendedora en @vhio.bsky.social, @icreacommunity.bsky.social y #Peptomyc. Muchas gracias a los estudiantes por invitarme! @msmelanoma.bsky.social

@lsouceklab.bsky.social @icreacommunity.bsky.social

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer Giuntini et al. demonstrate that Omomyc, the only direct MYC inhibitor currently in phase 2 clinical trials, causes DNA damage and synergizes with PARPis in triple-negative breast cancer. Their findin...

Link to the article: www.cell.com/cell-reports...

Huge thanks to Fabio Giuntini, and to the entire teams at
@vhio.bsky.social and #peptomyc for making this possible. We also want to acknowledge the support of
#AECMM and the @erc.europa.eu for backing research that can make a real difference.

In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.

Our work MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer has been accepted in
@cp-cellreports.bsky.social : 🚀

Encantada de participar en el Ennova Health Day representando a @vhio.bsky.social, @icreacommunity.bsky.social y #Peptomyc. Gracias a la organización, #DiarioMédico y a los colegas de mesa por un debate inspirador. La innovación nace en y para el hospital.

Encantada de participar en el Ennova Health Day representando a @vhio.bsky.social, @icreacommunity.bsky.social y #Peptomyc. Gracias a la organización, #DiarioMédico y a los colegas de mesa por un debate inspirador. La innovación nace en y para el hospital.

Mil gracias a la @fundacionfero.bsky.social por su invitación a impartir una Charla Científica en el Circulo Ecuestre y contar el desarrollo de nuestra terapia para el tratamiento del cáncer.
🙏🏻 Gracias FERO por vuestro apoyo continuo a la investigación contra el cáncer! @vhio.bsky.social #peptomyc

Este lunes, a las 19:00, tendré el placer de dar una charla para la @fundacionfero.bsky.social en el Círculo Ecuestre en Barcelona , contando el viaje que recorrió nuestro fármaco desde el laboratorio hasta los ensayos clínicos.
Para registrarte: administracion@circuloecuestre.es

Honored to give the closing talk at the inaugural #GordonResearchConference (#GRC) on #Microproteins tomorrow in Castelldefels, Spain. Excited to share our latest work on developing a clinically viable MYC inhibitor and wrap up an incredible week of cutting-edge science. @vhio.bsky.social #peptomyc

MYC in cancer: from undruggable target to clinical trials Nature Reviews Drug Discovery - Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on...

We are delighted to share that our review “MYC in cancer: from undruggable target to clinical trials” is finally out in Nature Reviews Drug Discovery. What an amazing journey this has been and still promises to be! Big thanks to co-author Jonathan Whitfield. @vhio.bsky.social
rdcu.be/eawOK